SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-17-005313
Filing Date
2017-08-18
Accepted
2017-08-18 16:18:23
Documents
5
Period of Report
2017-09-15
Effectiveness Date
2017-08-18

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2233043zdef14a.htm DEF 14A 502654
2 G312275.JPG g312275.jpg GRAPHIC 11512
3 G761950.JPG g761950.jpg GRAPHIC 7584
4 G200434BEI001.GIF g200434bei001.gif GRAPHIC 116387
5 G200434BEI002.GIF g200434bei002.gif GRAPHIC 98844
  Complete submission text file 0001047469-17-005313.txt   826933
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37558 | Film No.: 171041309
SIC: 2834 Pharmaceutical Preparations